| Heart Failure (HF) |
1 |
1 |
| Arrhythmia |
0 |
0.9 |
| Pacemaker |
0 |
0.72 |
| Atrial Fibrillation |
0 |
0.66 |
| Cardiac Resynchronization Therapy |
0 |
0.56 |
| Cardiovascular Imaging |
0 |
0.47 |
| Beta-Adrenergic Agonist |
0 |
0.44 |
| Heart |
0 |
0.39 |
| Atrioventricular Block |
0 |
0.33 |
| Hypertension |
0 |
0.31 |
| Ejection Fraction |
0 |
0.99 |
| Clinical Guidelines |
0 |
0.11 |
| Clinical Research |
0 |
0.11 |
| Minnesota |
0 |
0.11 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Myocardial Infarction (MI) |
0 |
0.09 |
| B-Type Natriuretic Peptide |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Quality of Life |
0 |
0.06 |
| SGLT2 Inhibitor |
0 |
0.06 |
| Sinus |
0 |
0.06 |
| South Carolina |
0 |
0.06 |
| Ventricular Dyssynchrony |
0 |
0.06 |
| Vermont |
0 |
0.06 |
| Otolaryngology |
0 |
0.05 |
| Type 2 Diabetes Mellitus |
0 |
0.05 |